Results 181 to 190 of about 7,686 (201)

Alirocumab/evolocumab

Reactions Weekly, 2018
  +4 more sources

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

New England Journal of Medicine, 2015
Marc S Sabatine, Robert P Giugliano, Frederick J Raal   +2 more
exaly  

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Journal of the American College of Cardiology, 2020
Santos Rd, Santos R, Dirk J Blom, Handrean Soran   +2 more
exaly  

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

Lancet Diabetes and Endocrinology,the, 2016
Naveed Sattar, Jennifer G Robinson, Frederick J Raal   +2 more
exaly  

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Journal of the American College of Cardiology, 2014
Erik S G Stroes, David R Sullivan, Robert S Rosenson   +2 more
exaly  

Anti-PCSK9 Monotherapy for Hypercholesterolemia

Journal of the American College of Cardiology, 2014
Maria Laura Monsalvo
exaly  

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Journal of the American College of Cardiology, 2014
Frederick J Raal, Robert P Giugliano, Marc S Sabatine   +2 more
exaly  

Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

Journal of the American College of Cardiology, 2019
Konstantinos C Koskinas, Stephan Windecker, Christian Mueller   +2 more
exaly  

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

New England Journal of Medicine, 2014
Dirk J Blom, Richard Ceska, Eli M Roth
exaly  

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role

Journal of Lipid Research, 2016
Frederick J Raal, Robert P Giugliano, Marc S Sabatine   +2 more
exaly